

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF OPERATING OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of Everest Medicines Limited (the “**Company**”) announces that Mr. Xiaofan Zhang (“**Mr. Zhang**”) has resigned as an executive Director and the Chief Operating Officer of the Company with effect from 31 March 2023 to devote more time to his other business endeavours.

Mr. Zhang has confirmed that he has no disagreement with the Board and that there are no other matters that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited in respect of his resignation.

The Board wishes to express its sincere gratitude to Mr. Zhang for his invaluable contributions to the Company during his tenure of service.

By order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, 31 March 2023

As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.